RECRUITING

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Official Title

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Quick Facts

Study Start:2023-04-07
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05746182

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Histologically confirmed PanNEN.
  2. 2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years).
  3. 3. Participants willing and able to comply with the study procedures.
  1. 1. Inability to provide informed consent.
  2. 2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:
  3. 1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
  4. 2. Active hematologic malignancy.
  5. 3. History of allogenic bone marrow transplant or stem cell transplant.

Contacts and Locations

Study Contact

Paige Steiding
CONTACT
(415) 514-6314
Paige.Steiding@ucsf.edu

Principal Investigator

Emily Bergsland, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, Los Angeles
Los Angeles, California, 90095
United States
Univeristy of California, San Diego
San Diego, California, 92093
United States
University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Emily Bergsland, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-07
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-04-07
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Genetic Assay
  • Biomarkers

Additional Relevant MeSH Terms

  • Pancreatic Neuroendocrine Neoplasm